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The human gastric microbiota: Is it time to
rethink the pathogenesis of stomach diseases?
Gerardo Nardone and Debora Compare
Abstract
Introduction: Although long thought to be a sterile organ, due to its acid production, the human stomach holds a core
microbiome.
Aim: To provide an update of findings related to gastric microbiota and its link with gastric diseases.
Methods: We conducted a systematic review of the literature.
Results: The development of culture-independent methods facilitated the identification of many bacteria. Five major phyla
have been detected in the stomach: Firmicutes, Bacteroidites, Actinobacteria, Fusobacteria and Proteobacteria. At the genera
level, the healthy human stomach is dominated by Prevotella, Streptococcus, Veillonella, Rothia and Haemophilus; however,
the composition of the gastric microbiota is dynamic and affected by such factors as diet, drugs and diseases. The interaction
between the pre-existing gastric microbiota and Helicobacter pylori infection might influence an individual’s risk of gastric
disease, including gastric cancer.
Conclusions: The maintenance of bacterial homeostasis could be essential for the stomach’s health and highlights the
chance for therapeutic interventions targeting the gastric microbiota, even if gastric pH, peristalsis and the mucus layer
may prevent bacteria colonization; and the definition of gastric microbiota of the healthy stomach is still an ongoing
challenging task.
Keywords
Gastric cancer, gastric microbiota, gastritis, Helicobacter pylori, review, stomach bacteria, stomach cancer
Received: 27 October 2014; accepted: 7 December 2014
Introduction
Interest in the microbiologic composition of the normal
digestive tract started in the 19th century, when Louis
Pasteur stated that ‘‘life without bacteria would be
impossible.’’ A few years later, Elie Metchnikoﬀ postu-
lated that lactic acid bacteria have health beneﬁts cap-
able of promoting longevity. Today, humans are
considered superorganisms constituted by cells and
symbiotic microorganisms, although the number of
microorganisms that colonize the human body is
10 times the number of human body cells, and the
number of microorganism genes is 150 times the
number of human genes.1 Therefore, research on
human diseases must include the microbiome, to
obtain a complete picture of a given condition.
In 2000, the editors of Science prophesized that
‘‘human microbe research will become the new hot
topic worldwide.’’2 In 2007, the US National Institute
of Health (NIH) launched the Human Microbiome
Project.3 Just 1 year later, the European Union (EU)
funded a project devoted to the metagenomics of the
human intestinal tract. Finally, in 2009, the
International Human Microbiome Consortium began
to explore the relationship between microbiota and
human health and disease.4,5 Since then, a huge
amount of data, prevalently on gut microbiota, has
been produced; and the time seems ripe to draw
together the various research threads. Here we review
the latest ﬁndings related to the composition of the gas-
tric microbiota, the factors that modulate it, and the
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relationship between gastric microbiota and
Helicobacter pylori (H. pylori) infection.
Composition of the gastric microbiota
Research on gastric microbiota laid dormant for many
years, mainly as a consequence of the dogma that, due
to its acid production, ‘the stomach is a sterile organ’
inhospitable to bacteria. In addition, the reﬂux of bile
acids in the stomach, the thickness of the mucus layer
and the eﬀectiveness of gastric peristalsis might have
impeded bacterial colonization of the stomach.
Furthermore, the nitrate contained in saliva and food
is converted by Lactobacilli present in the mouth into
nitrite that, once in the stomach, is transformed by gas-
tric juice into nitric oxide, a strong antimicrobial agent.
All these factors, together with technical diﬃculties in
collecting samples for analysis, and the lack of simple,
reliable diagnostic tests have hampered the challenging
study of the gastric microbiota.6,7
The discovery of Campylobacter pyloridis by Robin
Warren and Barry Marshall in 1982 demolished the
dogma of the sterile stomach. The bacterium, renamed
H. pylori in 1984, colonizes and damages the gastric
mucosa by a complexity of bacterial mechanisms.
H. pylori escapes gastric elimination, due to the
urease enzyme, which produces ammonia from urea.
Ammonia neutralizes acid, thereby enabling the bacter-
ium to penetrate the mucus layer, colonize the epithe-
lium and foster the complex inﬂammatory response
that damages the gastric mucosa and leads to chronic
gastritis in the majority of infected people, or to peptic
ulcer in a subgroup (10%), and to gastric malignancies
in a minority (<1%).
In 1981, a few months before the discovery of
H. pylori, The Lancet reported that a large number of
acid-resistant bacterial strains are detectable in the
stomach, among which are Streptococcus, Neisseria
and Lactobacillus. The presence of these bacteria is
not surprising, as the stomach is exposed to swelling
of bacteria from the oral cavity and reﬂux of bacteria
from the duodenum. More than 65% of phylotypes
identiﬁed in the stomach have been described in speci-
mens from the human mouth.8 Thus, such species of
bacteria as Veillonella, Lactobacillus and Clostridium,
that are found in gastric juice may just be transient.9
Transient bacteria establish small colonies for brief
periods of time, without colonizing the gastric mucosa,
and do not cross talk with the host; however, whether
bacteria other than H. pylori colonize the gastric
mucosa and cross-talk with the host by penetrating
the thick mucus layer, is not known. Thus, the study
of the gastric juice alone for the presence of bacteria is
not conclusive, and it may underestimate the real pres-
ence of bacteria at the mucosal level. Indeed, while
Firmicutes, Bacteroidetes and Actinobacteria dominate
the gastric ﬂuid samples, Firmicutes and Proteobacteria
are the most abundant phyla in gastric mucosal sam-
ples.10 In addition, the identiﬁcation of bacterial strains
by conventional culture-based methods provides an
incomplete and biased picture of the biodiversity of
gastric microbiota, because more than 80% of micro-
organisms are uncultivable.11,12 Recently, the develop-
ment of culture-independent molecular methods based
on 16S rRNA genes, such as ﬂuorescent in situ hybrid-
ization, dot-blot hybridization with rRNA-targeted
probes, denaturing gradient gel electrophoresis, tem-
perature gradient gel electrophoresis, and cloning and
sequencing of rDNA have facilitated the identiﬁcation
and classiﬁcation of gastrointestinal bacteria.13
Bik et al.10 analyzed for the ﬁrst time the gastric
mucosa of 23 healthy adult subjects using a small sub-
unit 16S rDNA clone library approach: They identiﬁed
1056 non-H. pylori clones, 127 phylotypes and ﬁve
dominant genera (Streptococcus, Prevotella, Rothia,
Fusobacterium and Veillonella). A few years later,
Li et al.14 analyzed the gastric microbiota of 10 healthy
subjects, by cloning and sequencing 16S rRNA, and
identiﬁed 1223 non-H. pylori clones, 133 phylotypes
and ﬁve dominant genera (Streptococcus, Prevotella,
Neisseriae, Haemophilus and Porphyromonas). In
2013, Engstrand et al.15 investigated the gastric micro-
biota of 13 healthy subjects by pyrosequencing, iden-
tifying 200 phylotypes and ﬁve dominant genera
(Prevotella, Streptococcus, Veillonella, Rothia,
Pasturellaceae), and they did not diﬀer by comparing
antrum versus body.
In the same year, Delgado et al.16 analyzed gastric
juice and gastric biopsy samples of 12 healthy subjects
by culturing and pyrosequencing, and found that the
most abundant genera were Streptococcus,
Propionibacterium and Lactobacillus. Although these
studies examined diﬀerent populations (African-
American, Hispanic, Chinese and European subjects),
the gastric microbiota at both the phyla and genera
level, was surprisingly similar in all of them, even if
with a large degree of inter-subject variability.
Factors affecting the composition of gastric
microbiota
The composition of gastric microbiota at the genera
level is dynamic and is aﬀected by such factors as diet-
ary habits, medication use, inﬂammation of gastric
mucosa and, of course, H. pylori colonization. While
many studies document the eﬀect of diet on gut micro-
biota composition in humans,17–21 there are only a few
with evidence, mainly limited to animal model studies,
addressing the eﬀects of diet on gastric microbiota. An
in vivo study shows higher levels of total aerobes, total
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anaerobes, and Lactobacilli in the stomach of mice fed
a non-puriﬁed diet (natural source-derived food), with
respect to mice fed a puriﬁed diet (reﬁned food). This
increase correlates with lower levels of Toll-like recep-
tor 2 (TLR-2) mRNA in the stomach.22
The long-term use of proton pump inhibitors (PPIs)
and H2-antagonists, as well as atrophic gastritis, aﬀects
the composition of the gastric microbiota; this is not
surprising, considering that gastric microbiota depends
on gastric acid secretion. Bacterial overgrowth occurs
when the gastric pH was >3.8.23 Oro-pharyngeal-like
bacteria and fecal-like bacteria are signiﬁcantly more
abundant in patients on PPI therapy than in patients
on H2-antagonists and untreated control subjects.
24
Treatment for 2 weeks with PPI reduces gastric acid
secretion by 75% and this was suﬃcient to permit bac-
terial colonization of the stomach in healthy volun-
teers.23 Omeprazole (40mg/day) for 3 months induced
gastric bacterial overgrowth in 10 of 30 patients, com-
pared with 1 of 10 control subjects; however, after only
14 days of PPI treatment (omeprazole 30mg/day), the
total number of gastric bacteria had increased to a sig-
niﬁcant level.25
Antibiotics are known to have negative ecological
eﬀects on gastrointestinal microﬂora. Animal studies
show that penicillin treatment reduces Lactobacilli
populations and promotes yeast colonization of the
gastric epithelium. Using culture-dependent and cul-
ture-independent approaches, Mason et al.26 demon-
strated that cefoperazone treatment in the human
causes long-term alteration of gastric microbiota, such
as a signiﬁcant reduction in the number of Lactobacilli
and overgrowth of Enterococci.
Relationship between Helicobacter pylori and
gastric microbiota
Studies in animal models show that long-term H. pylori
infection aﬀects the bacterial composition of the gastric
microbiota. Indeed, an abundance of Eubacterium
cylindroides and Prevotella species and a decrease of
Biﬁdobacterium species, Clostridium coccoides and
Clostridium leptum were found in H. pylori-negative,
but not in H. pylori-positive gerbils.27 Studies con-
ducted in patients without H. pylori infection reveal
that they have a relative lack of Proteobacteria and
Bacteroidetes phyla, and a relative abundance of
Streptococcus and Prevotella genera.14 In H. pylori-
positive patients, with respect to H. pylori-negative sub-
jects, Maldonado-Contreras et al.28 report a higher
abundance of Proteobacteria, Spirochetes and
Acidobacteria; and a decreased abundance of
Actinobacteria, Bacteroidetes and Firmicutes.
H. pylori-induced changes in gastric microﬂora can
be attributed to various factors. Long-term H. pylori
infection leads to gastric atrophy, and consequently,
to an increase of the gastric pH, which prompts the
colonization of the stomach by transient bacteria. In
addition, ammonia and bicarbonate produced by
H. pylori from urea may serve as substrates for other
bacteria. Finally, H. pylori slows gastric motility,
thereby favoring the clearance of adherent bacteria
from the mucosa.9 It is likely that H. pylori creates
special niches that allow the survival and colonization
of bacteria in the stomach. Notwithstanding these ﬁnd-
ings, the relationship between H. pylori and the gastric
microbiota is still controversial. Indeed, Tan et al.29
report that chronic H. pylori infection does not signiﬁ-
cantly alter the microbiota of the murine stomach.
Similarly, Bik et al.10 did not ﬁnd signiﬁcant diﬀerences
in gastric microbiota between H. pylori-positive and
H. pylori-negative patients, in terms of 16S rDNA
sequences. Very recently, Khosravi et al.30 conﬁrmed
these ﬁndings in a large sample of subjects, including
131 H. pylori-positive and 84 H. pylori-negative
patients.
It is likely that factors such as the degree of
H. pylori-related inﬂammation; the time of the infec-
tion; and the presence, type and extension of precan-
cerous lesions have to be taken into account, when
dealing with the composition of gastric microbiota.
Gastric microbiota and the diseased stomach
Animal and human studies indicate that gastric colon-
ization by bacteria that normally colonize the lower
bowel could aﬀect the outcome of H. pylori infection
and the risk of gastric cancer.31–34
In C57BL/6N mice grown in diﬀerent environments,
i.e. Charles River Lab and Taconic Farms, and then
infected with the same strain of H. pylori, the rate of
inﬂammation, gastritis and metaplasia was signiﬁcantly
greater in those mice grown in Charles River Lab.
Interestingly, the rate of gastric colonization by
Lactobacillus strains diﬀered signiﬁcantly between the
two groups of mice.35 These data are consistent with
the idea that mice from diﬀerent vendors will have dif-
ferent resident stomach microbial populations.
In addition, germ-free transgenic insulin-gastrin
(INS-GAS) mice, a mouse model of gastric cancer,
developed gastric intraepithelial neoplasia with a
marked time delay when infected with H. pylori
alone, compared with those infected with H. pylori
plus a normal complex gastric microbiota.36 Similarly,
the colonization of the stomach by an artiﬁcial intes-
tinal microbiota (‘Altered Schaedler’s Flora’, including
Clostridium species, Lactobacillus murinus and
Bacteroides species) increased the incidence of gastric
intraepithelial neoplasia up to 69% in male INS-GAS
mice, 7 months after H. pylori infection.37
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Finally, antibiotic treatment signiﬁcantly delayed the
onset of gastric neoplasia in Helicobacter-free and spe-
ciﬁc pathogen-free INS-GAS mice.38
A culture-based study of 103 biopsies from
H. pylori-infected patients showed that the colonization
with non-H. pylori bacteria was higher in the non-ulcer
dyspepsia group than in the gastric ulcer group
(p< 0.001), which suggests a pathogenetic role of
non-H. pylori bacteria in non-ulcer dyspepsia.39 In add-
ition, a positive correlation was observed between
Streptococcus and peptic ulcer disease.30
Patients with antral gastritis, compared with
H. pylori-negative subjects, show a decrease of
Proteobacteria and an increase of Firmicutes at the
phyla level, and a signiﬁcant increase of Streptococcus
at the genera level, without signiﬁcant diﬀerences
between the gastric antrum and body, in both
groups.14 Similarly, patients with atrophic gastritis,
with respect to healthy subjects, had an increase of
Streptococcus and a decrease of Prevotella.15
Recently, a gradual shift in the gastric microbiota
proﬁle from non-atrophic gastritis to intestinal metapla-
sia, and then to intestinal-type gastric cancer, was
reported.40 Lower microbial richness (number of bacter-
ial genera per sample) in the upper digestive tract was
independently associated with a lower serum pepsinogen
I/pepsinogen II ratio, which corresponds to a cancer-
predisposing state in the stomach.41 Culture-based
analysis of patients with gastric cancer reveals more
microorganisms and more anaerobic bacteria (e.g.
Clostridium and Bacteroides species) than those from
normal mucosa.42 Patients with cancer had a relative
abundance of Streptococcus, Lactobacillus, Veillonella
and Prevotella; and a decrease of the H. pylori strain.42
Interestingly, Veillonella favors the accumulation of
nitrite in the stomach, thus promoting a carcinogenic
eﬀect.39 In this context, it is noteworthy that the concen-
tration of nitrite is signiﬁcantly higher in the gastric juice
of patients with gastric cancer, than in controls.43
Very recently, a 454 GS FLX Titanium-based ana-
lysis of the microbial composition, diversity and rich-
ness in gastric mucosa from patients with chronic
gastritis, intestinal metaplasia and gastric cancer
found a relative increase in the bacilli class in the gastric
cancer group, compared with the other groups.
Moreover, the Helicobacteraceae family was signiﬁ-
cantly lower in the gastric cancer group, compared
with chronic gastritis and intestinal metaplasia groups,
while the relative abundance of Streptococcaceae family
signiﬁcantly increased. In addition, the denseness and
diversity of gastric microbiota in the gastric cancer
group increased, compared with other groups.44
Overall, these data suggest that, in animal models,
and also probably in humans, the gastric microbiota
can aﬀect the immunobiology of the gastric mucosa,
and as a consequence, the outcome of H. pylori infec-
tion and the related carcinogenic process.45
Nevertheless, a unique bacterial proﬁle has not yet
been identiﬁed, and the mechanistic link to cancer
needs to be clariﬁed.
Conclusions
The discovery of H. pylori demolished the historical
dogma of medicine that ‘the stomach is a sterile
organ’. Current data suggest that the healthy human
stomach holds a core microbiome dominated by
Prevotella, Streptococcus, Veillonella, Rothia and
Haemophilus. A shift in abundance of Firmicutes
phylum and the Streptococcus and Prevotella genera
can be found in the H. pylori-infected stomach and in
gastric cancer. The pharmacological inhibition of gas-
tric acid secretion and gastric atrophy enable the sur-
vival and proliferation of other microbes that are
normally killed by acid.
Our understanding of gastric microbiota has
increased in recent years, but it is still unclear if and
to what extent H. pylori infection perturbs the gastric
microbiota, and if and to what extent the gastric micro-
biota modulates the outcome of an H. pylori infection.
Nevertheless, it is becoming evident that their inter-
action inﬂuences an individual’s risk of gastric disease,
including gastric cancer. Further studies in humans that
aim to clarify the composition of gastric microbiota,
and its role in health and disease, will be welcome.
What are the next steps?
Future studies concerning gastric microbiota should
include microbial and metabolomic proﬁles, correlated
with the natural history of speciﬁc diseases.
Subsequently, germ-free animals could be used to
understand the casual relationship between bacteria
and host disease. Once this step is reached, the possi-
bility of modulating the gastric microbiota with the aim
to change the natural course of diseases, or to prevent
them, could be addressed.
Advances in molecular technologies would allow
obtaining more data from a reduced amount of samples
at a lower cost, which will further enable more detailed
studies of the stomach microbiome, and will make data
available to a broader range of scientists.
Unraveling the molecular basis of bacteria-host
interactions will improve probiotic selection for diﬀer-
ent clinical indications.
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